(NASDAQ: ELDN) Eledon Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Eledon Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ELDN's revenue for 2028 to be $421,047,462, with the lowest ELDN revenue forecast at $421,047,462, and the highest ELDN revenue forecast at $421,047,462. On average, 1 Wall Street analysts forecast ELDN's revenue for 2029 to be $2,637,596,170, with the lowest ELDN revenue forecast at $2,637,596,170, and the highest ELDN revenue forecast at $2,637,596,170.
In 2030, ELDN is forecast to generate $4,670,239,090 in revenue, with the lowest revenue forecast at $4,670,239,090 and the highest revenue forecast at $4,670,239,090.